Long-term safety of tenapanor in patients with irritable bowel syndrome with constipation in the T3MPO-3 study.
Anthony J LemboKeith A FriedenbergRonald P FogelSusan EdelsteinSuling ZhaoYang YangDavid P RosenbaumWilliam D CheyPublished in: Neurogastroenterology and motility (2023)
Tenapanor was tolerable over ≥52 weeks of treatment and showed similar safety to that seen in shorter studies. Combined results of the T3MPO studies indicate that tenapanor is a valuable new treatment option for patients with IBS-C.